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Background 
Upper limb spasticity could occur to patients who 
had stroke and brain injury [1]. The spasticity had 
been defined by Lance [2] as the velocity-
dependent increase in the muscle tone which is 
due to the excitability of the stretch reflex. The 
spasticity affects the patients daily activities and 
mobility and also leads to pain and risk of falls [3]. 
Currently, Botulinum Toxin (BTX) treatment 
which is an injectable pharmacological agent has 
been proved an effective treatment for reducing 
the spasticity [4–6]. It improves patients upper 
limb dexterity in daily activities and increase the 
range of motion [7,8]. 
Traditionally, clinical scales are used to 
measure quality of life or the assessment of the 
motor function e.g. Fugl-Meyer [9] and Motor 
Assessment Scale [10]. The Modified Ashworth 
Scale (MAS) [11] widely used in clinical practice 
for evaluating upper limb muscle spasticity [12–
14]. MAS measure relies on the expertise of the 
clinicians and it is very subjective. A device - 
NeuroFlexor [15] was proposed to quantitatively 
measure the spasticity of the wrist and fingers 
muscles. Though NeuroFlexor can capture some 
quantitative measures but similar as the traditional 
MAS, it only focuses on the passive motion rather 
than the active motion.  
Functional recovery of the upper limb motion is 
extremely important in stroke rehabilitation, and it 
has been noted that the voluntary motion relates to 
the spasticity [1]. Though the above mentioned 
assessment methods are widely used, they are not 
able to capture the dynamic performance of the 
limb and the voluntary motion which is thought to 
be especially essential when assessing upper limb 
motor recovery. 
The Vicon system which is seen as a gold 
standard in motion monitoring and has been used 
to capture kinematic information changes [16] 
after the BTX treatment. However, the Vicon 
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Abstract 
Background: Muscle spasticity is a common motor complication after stroke and brain injury, and 
Botulinum Toxin is considered effective treatment for upper limb spasticity. However, clinical 
assessments are not possible to provide the quantitative measurement of changes happening on different 
upper limb segments. 
Methods: We aim to develop a multi-sensor system for quantitatively measurement of movement in all 
segments of upper limb. Five patients under neurorehabilitation were recruited to attend two-session 
rehabilitation assessment program to evaluate the changes before and one week after the Botulinum 
Toxin treatment. 
Results: Clinical assessments are all improved in general (Disability Assessment Scale: p<0.01). 
Analysis of Kinematic parameters and smoothness quantification parameters showed that number of 
movement units (p<0.05 for elbow and wrist), normalised jerk score are improved for all upper limb 
segments. 
Conclusions: This study demonstrate that our multi-sensor inertial sensing system can provide 
additional insights for motion quantification pre and post the Botulinum Toxin treatment.  
Keywords: Botulinum Toxin; Kinematics; Upper limb function, Quantitative measures 
system is complex in system set-up and is very 
expensive. With the emerging of the sensing 
technology, miniature wearable sensors for human 
movement tracking are becoming commercially 
available [17]. Studies have been done in 
measuring Range of Motion (ROM) [18] and 
movement coordination in neurological 
rehabilitation [19]. Additionally low cost sensors 
e.g. Microsoft Kinect has been used in human 
motion monitoring [20]. The analysis of the 
kinematics has shown the changes in the 
movement during the rehabilitation [21]. 
Especially, the movement smoothness calculated 
based on the kinematic measures has been used as 
an important indication of the performance 
evaluation of the upper limb motor function [22]. 
A number of parameters have been proposed for 
the quantification of the upper limb movement 
smoothness, for example, Number of Movement 
Units (NMU) [23], Normalised Jerk Score (NJS) 
[24].  
More recently, several studies have been 
carried out to explore the quantitative measures on 
muscle spasticity using wearable devices [25] and 
robot assisted tools [26], which are mainly focused 
on evaluation of upper limb spasticity after BTX 
treatment. More specifically, one study is focusing 
on quantitative spasticity of calf muscle [27]. 
Voluntary movement is considered important to 
the upper limb functioning in the daily lives of  
patients [28] and facilitating the optimal recovery 
of upper limb volunteer movement is a major 
concern in rehabilitation [29]. However, to our 
knowledge there is no study quantitatively 
assesses voluntary upper limb functions for the 
BTX efficacy using inertial sensors based systems. 
In our previous work, we proposed two sensing 
systems including a gold standard inertial sensing 
system and a gaming controller based system for 
upper limb rehabilitation assessment [30]. The 
system validation results demonstrated that both 
these systems were able to track the position 
within 0.5 cm over a 10 cm movement and 
orientation within 2.5 deg. In this study, we 
combine the traditional clinical assessments with 
kinematic and quantitative movement smoothness 
measures were calculated using the recorded data 
from inertial sensors attached on all four segments 
of the upper limb. First, in order to evaluate the 
usefulness of the kinematic and movement 
smoothness measures, each of the participants 
have been asked to perform a range of different 
tests including different range of motion tests and 
task-oriented test. Second, in order to understand 
the upper limb motion in a comprehensive way, 
the system captures the motion from all the upper 
limb segments by exploring the nature of the 
collected time series sensor data. Finally, the 
correlation between the clinical assessment, the 
kinematic measure and the quantitative 
smoothness measures has been explored. 
Furthermore, this multi-sensor system makes it 
feasible to the understanding of the coordination 
between different upper limb segments which are 
still a challenge for researchers [31,32]. 
Furthermore, this system aims to bridge the gap 
between the research and clinical practice for the 
upper limb motion assessment. In comparison with 
the traditional clinical scores carried out by 
clinicians using different standard clinical 
assessment scales, the proposed multi-sensor 
system provides an in-depth and comprehensive 
understanding of patients performance pre- and 
post the BTX treatment. It can also help clinicians 
with the therapeutic planning to improve patients’ 
upper limb function restore and provide the 
opportunity to automate the process of upper limb 
motion assessment in clinical setting. In addition, 
with the emerging of the low cost wearable inertial 
sensors, it is possible to build a system for patients 
to use remotely. 
Methods 
Participants recruitment 
Five patients have been recruited in this study 
and the patients information are listed in Table 1. 
Patients consented for this study and they were 
consecutive clinic patients in Kent Canterbury 
Hospital. We included patients who had confirmed 
focal spasticity. A clinical decision was taken by 
Neurorehabilitation Specialist to try Botulinum 
toxin intramuscular injection as part of treatment, 
and patients agreed to that treatment as per usual 
clinical care. They were all outpatients with no 
specific therapy following the BTX treatment. The 
BTX treatment was treated based on the spasticity 
of each patient and the details of the BTX dose 
and muscle injected are presented in Table I. This 
study had been carried out in a quiet room at 
University of Kent by a researcher. The patients 
were accompanied with their carers if needed. 
Before the study, all the patients signed an 
informed consent document which had been 
reviewed and approved by the UK NHS National 
Research Ethics Committee and the Hospital  
Patient Age Gender 
Handedness 
prior to stroke 
Time since 
stroke (yrs) 
Brain Lesion BTX Dose Muscle Injected 
1 52 Male Right 3 Stroke 
200 units (Dilution 
with 4ml normal 
saline) 
brachioradialis, FDP, 
FDS, bioep and 
pectoralis major 
2 72 Male Right 2 Right MCA 
300 units (Dilution 
with 4ml normal 
saline) 
Bicep, FDP, FDS 
3 76 Male Right 4 
Right thalamic 
infarct 
300 units (Dilution 
with 3ml normal 
saline) 
Pectoralis Major, FDP, 
FDS, FCR, FCU 
4 75 Female Right 4 
Right MCA 
infarction infarct 
200 units (Dilution 
with 4ml normal 
saline) 
FDP, FDS, Bicep, and 
Brachioradialis 
5 69 Male Right 2 
Right MCA 
infarction infarct 
200 units (Dilution 
with 4ml normal 
saline) 
FDP, FDS, Bicep 
Acronym: FDP: Flexor Digitorum Profundus, FDS; Flexor Digitorum Superficialis, FCU: Flexor Carpi Ulnaris, FCR: Flexor Carpi Radialis 
 
Table 1 Patient Information and BTX treatment Information 
 
 
Institutional Review Board (IRB) prior to the 
study. 
Clinical measurements 
The clinical tests include Disability Assessment 
Scale (DAS) [33], MAS and Motor Assessment 
Scale. All the patients were assessed using clinical 
assessment scales i.e (DAS, MAS and Motor 
Assessment Scale) and were asked to perform all 
the upper limb function experiment tests. A range 
of clinical tests have been carried out prior to the 
experimental tests using proposed sensing system. 
These assessment tests are widely accepted for 
rehabilitation assessment. The patients may not be 
able to complete all the assessment items in Motor 
Assessment Scale due to the upper limb disability. 
Measurement system and kinematic model 
Two monitoring system has been proposed in this 
study. One is gold standard four sensor Xsens [34] 
MTx sensing system and the other is low cost two 
sensor gaming sensing system. A system set-up of 
two systems has been shown in Fig. 1. In this 
paper, only the kinematic data recorded from MTx 
four sensor system are analysed and reported. This 
study aims to understand the upper limb functional 
performance before and after BTX treatment using 
inertial sensor-based system. The experiment tests 
are focusing on the active range of motion of the 
upper limb and upper limb functionality. 3D 
acceleration and 3D angular velocity were 
captured using the four wearable sensors from 
Xsens. Two kinematic models used to obtain the 
position tracking during all the experimental tests 
can be found in the previous study [21]. 
 
 
Figure 1. Quantitative Measurement multi-sensor system 
set-up (Two monitoring systems: Xsens MTx system & 
Sony Move gaming controller system) 
 
The gold standard Xsens MTx sensing system 
measures the 3D acceleration, 3D rate of gyro, 3D 
magnetic field. It can also provide 3D orientation 
(Roll, Pitch and Yaw) with a built-in sensor fusion 
algorithm. The upper limb positions and trajectory 
were calculated by the implementation of a 
kinematic model developed in our previous study 
[21]. The low-cost gaming sensing system uses 
Sony Move gaming controller [35] as it can also 
measure raw data from a 3D accelerometer, 3D 
gyroscope and 3D magnetometer. Post-processing 
is required to calibrate the gaming sensors and 
applying sensor fusion algorithms e.g. 
complementary filter and Kalman filter. The 
detailed calibration of the gaming sensor and 
implementation of the sensing fusion has been 
reported in our previous work [30]. 
Experiment tests  
In this study, in order to better understanding of 
the upper limb functions of the patients, a range of 
experimental tests have been done (See Fig. 2). A 
detailed description of the experiments is 
presented in subsections below. However, due to 
the patient’s upper limb function limitations, some 
of the tests had not been completed or only 
partially completed. 
Active Range of motion test (AROM) 
The range of motion test is shown to be a reliable 
test for the assessment of the upper limb functions 
[36]. In clinical assessment, the range of motion is 
normally measured by a goniometer. Compared 
with the goniometer, our sensing system can 
capture the dynamic changes of the upper limb 
motion during the assessment besides the range of 
motion value. In this work, a number of active 
range of motion (Fig. 2 (a)) with regard to 
different upper limb segments are considered 
including: shoulder flexion, shoulder abduction, 
patients were asked to perform the tests using their 
affected side. If they cannot complete the task with 
the affected side, they can use their unaffected side 
to assist. The patients task completion 
performance is shown in Table 2.   
Drinking test 
The drinking test (Fig. 2 (b)) in this study is to 
evaluate the functional performance in daily life, 
especially the drinking action involves stretching 
the hand to reach the cup placed in the middle of 
the table and bring it to the mouth and finally put 
the cup back on the table [37]. There is no water in 
the mug and the patient is only asked to mimic the 
drinking action. Typically, drinking test is 
composed of 5 stages, reach->grasp->transport-
>release->return. 
Bean bag test (BBT) 
In bean bag test (Fig. 2 (c)), 4 Small bean bags 
were place on the table. The patients asked to pick 
up one bean bag at a time and release at a pointed 
location on the table which is 20cm distance from 
the original location of the bean bag. The 
completion of the Bean bag test requires the 
coordination of multiple upper limb segments. 
Nine Hole Peg Test (NHPT) 
NHPT [38] (Fig. 2 (d)) is considered as the gold 
standard assessment of the impaired manual 
dexterity focusing the patients and had been 
frequently used in the clinical assessment [39]. 
NHPT requires the finger movements to handle the 
small pegs which is difficult for the selected 
participants in this study since the BTX treatment 
in this study is focusing on the upper arm and 
forearm muscles (details can be found in Table 1). 
However, in this study, none of the patients was 
able to perform the NHPT due to their severe 




In this work, on the consideration of the small 
number of samples, the paired t test was applied to 
both the clinical assessment scales measures and 
kinematic experimental tests (for kinematics and 
movement smoothness quantification parameters) 
to compare from pre- to post-BTX treatment. The 
statistical tests were conducted using IBM SPSS 
Version 25, with p<0.05 regarded as significant. 
Tri-axis accelerometer, gyroscope and 
magnetometer signals were recorded and a multi-
segment kinematic model for trajectory monitoring 
[21] is developed in Matlab (MathWorks). 
Kinematic measurement and quantification of 
movement smoothness 
Joint Range of Motion (ROM) and Joint position 
are the two most important parameters for the 
kinematic measurement for the upper limb motion 
monitoring. The visualisation of the range of 
motion and the position in time series give 
additional insights for the clinicians and help them 
understand the upper limb motion in an intuitive 
manner. 
Total Acceleration and Total Velocity 
Total acceleration is calculated using the equation 
below which is the normalised acceleration with 
the gravity removed. 
 gAAAA zyxtotal 
222
 
Speed of movement is fundamental to human 
movements [40]. Total velocity is calculated using 
the equation (2) below. 

222
zyxtotal VVVV   
       
Shoulder flexion & extension Shoulder abduction & adduction  Shoulder internal & external rotation 
   
Elbow flexion and extension; Forearm pronation & supination; Hand flexion & extension; Radial Deviation & Ulnar 
Deviation 
(a) Upper limb AROM test 
  
(b) Drinking test           (c) Bean Bag test 
 
(d) NHPT 
Figure 2. Illustration of the Experimental Tests (a) Upper limb AROM test (b) Drinking test (c) Bean Bag test (d) NHPT 
 
Range of Motion and Position Tracking 
ROM is calculated for each of the range of motion 
test for all the participants using the equation (3).  
 minmax  ROM  
Movement Smoothness 
Movement smoothness is an important aspect used 
in assessing upper limb motion. And in evaluation 
of the patient’s motor recovery, it has been 
investigated in stroke patients. There are a few 
useful parameters which have been used in 
quantitation of smoothness measures including 
NMU and NJS. The parameters for movement 
smoothness were calculated for all the participants. 
NMU 
Considered as a useful parameter used in the 
quantitative measurement of movement 
smoothness, NMU has been used to analyse the 
movement of upper limb segments including upper 
arm, lower arm, shoulder and hand in this work. It 
is defined as the total number of zero crossings in 
the acceleration signal [23], which is also the 
number of the velocity maximum during the 
movement period. Usually the visual presentation 
of the healthy volunteers’ movement data 
(orientation or position) against time will be very 
smooth with clear peaks in acceleration and 
velocity. In contrast, the patient’s movement may 
have a jerkier movement with multiple peaks and 
irregularities. A smaller value of NMU indicates a 
smoother movement. 
NJS 
The NJS is another estimate of the movement 
smoothness related to stroke patients’ movement 
for the evaluation of the sudden change of the 
movement and is an indication of the trajectory 
smoothness [24]. The value of the NJS will 
decrease while the trajectory is getting smoother. 
The evaluation of this variable will be carried out 
on a range of experimental measurements of the 
healthy volunteers and patients. Equation (4) [24] 
below is used to calculate the NJS. In this 
equation, the third derivative of the position with 





















































where NJS: Normalised Jerk Score, t1 and t2: 
start and end of the motion time, t: movement 
time, l: movement distance, (x, y, z): position 
coordinates. 
Movement Trajectory 
It has also been noted that patient movement has 
more submovements than healthy volunteers. It 
has been proposed that a measure related to the 
length of the position trajectory can be used as a 
quantitative vector to evaluate the subject’s 
performance. The length of the 3D trajectory is 
calculated using the equation below. 













As described in the Section of Experiment 
Tests, all four upper limb joints/segments 
(Shoulder, Elbow, Wrist and Hand) are 
measurement by 4 inertial sensors. The sample 
rate is 50Hz. Two most important measurements 
parameters are orientation and trajectory tracking 
of the different segments. Besides, a series of 
parameters have been calculated to assess the 
performance of the rehabilitation including total 
velocity, total acceleration, NMU, and NJS. All 
the above parameters have been calculated for all 
the experiment tests described above. 
Results 
All the five patients had attended for two sessions 
for experiment tests. The pre- test was done before 
the injection of BTX and the post- test was done 
one week after the injection. The Patient No.2 had 
completed additional two follow-up sessions with 
one week interval. Table 2 is an overview of the 
task completion status for each patient and some 
tests had only partially completed with assistance 
from less affected side. All the patients were able 
to complete the tests such as Bean Bag Test and 
Drinking Test which mainly using gross motor 
dexterity of the affected upper limb. For AROM 
tests, Shoulder flexion & extension and Elbow 
flexion & extension are the top completed tasks. 
None of the patients were able to complete the 
NHPT since it requires distal manipulation and 











































1 P-C   P-C    P-C P-C  20% 
2 C   C    C C  40% 
3 C   C  C  C C  50% 
4 C  C P-C    C C  45% 










































1 C   C    C P-C  35% 
2 C C C C    C C  60% 
3 C C C C C C  C C  80% 
4 C  C P-C  P-C  C C  50% 
5 C C C C C C C C C  90% 
C: Completed, P-C: Partial Completed 
Table 2 Patient Test Completion Review 
 
the task completion rate of patients increased 
significantly (p=0.011). 
Clinical outcome measures 
The scores of DAS, MAS and Motor Assessment 
Scale were compared before the BTX injection 
and one week after injection. Clinical assessment 
scores for the pre- and post- BTX treatment has 
been presented in Table 3-5. DAS scores for the 
Limb posture improved significantly (P = 0.004) at 
post-BTX treatment, and the sum of the DAS 
scores improved significantly (P=0.005). MAS 
scores for the shoulder, elbow, wrist, fingers and 
Thumb all decreased indicates the reduce of the 
muscle spasticity. Scores for Motor Assessment 
Score show that scores in sitting G1 (p=0.007) and 
in Advanced H3 (p=0.033), H4 (p=0.025) and H5 
(p=0.035) improved significantly post-BTX. 
Orientation and position trajectory tracking 
visulisation 
The Fig. 3 shows orientation and position tracking 
of elbow flexion test of a healthy volunteer and a 
patient the pre and post the BTX treatment. There 
is visible changes of the trajectory and orientation 
tracking for different patients. Fig. 3 shows a 
comparison between a patient position trajectory 
tracking with a health volunteer. The visualisation 
of the range of motion and position trajectory 
tracking can be useful through observation of the 
DAS Measures Mean ± Std P-Value 
 Pre- Post-  
Hygiene 1±0 0.8±0.447 0.374 
Dressing 1.8±0.447 1.8±0.447 - 
Limb Posture 2.4±0.548 1.2±0.447 0.004 
Pain 0.2±0.47 0.2±0.447 - 
All 5.4±1.140 4±0.447 0.005 
Table 3 Assessment scores for DAS pre- and post- BTX 
injection 
 
MAS Measures Mean ± Std P-Value 
 Pre- Post-  
Shoulder 2.8±1.304 2.4±1.140 0.178 
Elbow 4.0±1.225 3.4±0.894 0.07 
Wrist 3.8±1.643 3±1 0.294 
Fingers 3.2±1.304 2.2±0.837 0.089 
Thumb 3.2±1.304 2.2±0.837 0.089 
All 17±5.874 13.4±4.099 0.113 
Table 4 Assessment scores for MAS pre- and post- BTX 
injection 
 
clinicians and researchers. It can be seen from Fig. 
3 that the movement after BTX treatment is much 
smooth compared with the movement before BTX 
treatment. In order to quantify these changes, 
Kinematic parameters and parameters from 
quantification of the movement smoothness have 
been used to provide additional insights for 
clinicians. Fig. 4 and Fig. 5 show the position 
tracking of 3 axes for both healthy volunteer and 
patients in bean bag test and drinking test 
respectively. In Fig. 4 and Fig 5, "ph-x", "ph-y", 
"ph-z" are the positions of the hand in x, y and z 
plane. Fig 6 and Fig 7 show the multiple trials 
results for both healthy volunteer and patients.  
 
Motor Assessment Scale Measures Mean ± Std P-Value 
  Pre- Post-  
In Lying 
F1 3.6±2.074 4±1.581 0.374 
F2 3.8±2.168 4±1.581 0.621 
F3 1.4±1.949 3.8±2.168 0.061 
F4 3.4±1.817 3.8±1.095 0.477 
F5 2.8±1.789 3.2±0.837 0.541 
F6 0.4±0.894 0±0 0.374 
F-All 15.4±9.209 18.8±6.907 0.202 
In Sitting 
G1 0.6±1.343 3.2±0.836 0.007 
G2 0±0 2±1.225 0.022 
G3 0.8±1.789 2±1.414 0.07 
G4 2.8±1.095 3.4±1.342 0.426 
G5 1.4±1.949 2.6±1.949 0.178 
G6 0.6±0.894 1±1.414 0.178 
G-All 6.2±4.817 14.2±3.768 0.006 
Advanced 
H1 1±1.732 2.2±1.095 0.07 
H2 0.4±0.894 0.6±1.342 0.374 
H3 0.4±0.894 1.6±1.140 0.033 
H4 0.6±1.342 2±1.871 0.025 
H5 1±1.732 2.6±1.140 0.035 
H6 0.4±0.894 1.6±0.894 0.07 
H-All 3.8±5.495 10.6±4.827 0.006 
Table 5 Assessment scores for Motor Assessment Score pre- and post- BTX injection 
 
Kinematic parameters pre- and post-BTX 
treatment 
For movement smoothness quantification, three 
quantification parameters improved significantly 
from pre-to post-BTX treatment as shown in Table 
6. In general, NMU, NJS and movement trajectory 
for all the upper limb segments are improved. 
NMU decreased at all the four upper limb 
segments after the BTX treatment and the 
significant decrease is for wrist (p=0.039) and 
elbow (p=0.037) which is a strong indication of 
the movement improvement. The value of the total 
velocity increased while the value of the total 
acceleration decreased, which explains the fact the 
patients completed the experimental quicker but 
the movement is much smoother after the BTX 
treatment. 
Comparisons between the Statistical analysis 
with the kinematic measures on the changes 
pre and post BTX treatment 
Correlations have been explored between the 
changes of the clinical assessment measures and 
kinematic measure regarding different upper limb 
segments. The results are presented in Table 7. 
The total acceleration shows good correlation with 
MAS score on the elbow (r=0.946, p=0.054) and 
wrist (r=0.726, p=0.274) joints while and total 
velocity significantly correlated with MAS score 
on the hand (r=0.937, p=0.063) and shoulder 
(r=0.978, p=0.021).  
Discussion 
The aim of this study is to examine the changes 
pre and post the BTX treatment utilising kinematic 
measures in order to better understand the changes 
of upper limb motor function besides the 
spasticity. In order to understand the upper limb 
segments motor changes in a broader view, we 
recorded the sensors data from all four upper limb 
segments during a range of different rehabilitation 
experimental tests. All the clinical assessments are 
improved after the BTX treatment. The clinical 
assessments are focusing the completion of a 
specific target while the experimental tests for 
kinematic measures are focusing on understanding 
the performance of the different upper limb 
segments and coordination between these 
segments. The changing patter for each patient on 
different segments are different. The recovery of 
the movement for different segments can be 
complexed. By analysing the total acceleration of 
upper limb segments, it can be seen that for the 
experimental tests, the total acceleration is reduced 
especially for the wrist and elbow segments which 
contribute more during in the bean bag test and 
drinking test. It indicates that the patients are 







(a) Healthy Volunteer AROM   (b)  Healthy Volunteer 3D position trajectory 
  
(c) Patient 2 Pre BTX AROM   (d)  Patient 2 Pre BTX 3D position trajectory 
   
(e) Patient 2 Post BTX AROM   (f)  Patient 2 Post BTX 3D position trajectory 
 
Figure 3. Orientation and 3D position tracking before and after BTX treatment of Patient No.2 and Healthy Volunteer in an 
elbow flexion test. (in (b), (d) and (f), "ph-x", "ph-y", "ph-z" are the positions of the hand in x, y and z plane) 
 
   
(a) Patient 2 Pre-BTX     (b) Patient 2 Post-BTX 
  
(c) Patient 4 Pre-BTX      (d) Patient 4 Post-BTX 
 
 
(e) Healthy Volunteer 
 
Figure 4. 3D position tracking before and after BTX treatment of Patient No.2&4 and Healthy Volunteer in a bean bag test. 
 
  
(a) Patient 2 Pre-BTX position tracking on 3 axis (b) Patient 2 Post-BTX position tracking on 3 axis 
  




(e) Healthy volunteer position tracking on 3 axis (f) Healthy volunteer position tracking in 3D space 
 
 








(a) Patient 2 3D position Pre-BTX Bean Bag Test  (b) Patient 2 3D acceleration Pre-BTX Bean Bag Test  
 
  
(c) Patient 4 3D position Post-BTX Bean Bag Test  (d) Patient 4 3D acceleration Post-BTX Bean Bag Test 
 
  
(e) Healthy volunteer 3D position Post-BTX Bean Bag Test  (f) Healthy volunteer 3D acceleration Post-BTX Bean Bag Test 
Figure 6. Results from Multiple Trials for Patients and Healthy volunteers for a bean bag test.  
 
   
(a) Healthy volunteer 3D position    (b) Healthy volunteer 3D position in 3D plot   (c) Healthy volunteer 3D acceleration  
 
   
(d) Patient 2 3D position Pre-BTX (e) Patient 2 3D position Pre-BTX in a3D plot  (f) Patient 2 3D acceleration Pre-BTX  
 
   
(g) Patient 2 3D position Post-BTX (h) Patient 2 3D position Prost-BTX in a3D plot  (i) Patient 2 3D acceleration Post-BTX 
Figure 7 Results from Multiple Trials for Patients and Healthy volunteers for a drinking test.  
 
Parameters Upper limb segment Pre Post P-Value 
  Bean-Bag Test Drinking Test Bean-Bag Test Drinking Test  
MUN Elbow 223.3±110.0 67.9±28.7 155.8±76.2 52.4±10.7 0.037* 
 Wrist 245.0±90.2 72.3±20.9 194.0±113.7 49.8±10.7 0.039* 
 Hand 292.9±110.0 86.0±25.9 262.6±176.5 60.5±14.4 0.168 
 Shoulder 238.2±126.8 79.3±35.9 195.3±134.9 55.5±9.0 0.050 
NJS Elbow 157.5±100.0 3.0±1.0 63.3±50.5 1.6±1.1 0.160 
 Wrist 368.1±236.3 6.9±5.6 110.4±68.8 2.2±1.5 0.147 
 Hand 487.1±337.0 10.4±4.3 160.3±115.7 3.1±2.3 0.159 
 Shoulder 101.0±77.1 2.5±1.9 62.7±71.1 1.3±0.9 0.080 
Trajectory (mm) Elbow 298.4±129.5 53.5±13.9 224.8±41.8 59.3±17.5 0.310 
 Wrist 502.6±265.6 85.7±30.3 336.6±97.1 89.0±29.4 0.193 
 Hand 578.2±338.3 94.6±30.0 385.9±86.2 106.1±34.6 0.264 
 Shoulder 282.4±58.7 58.0±6.4 244.0±16.4 64.4±14.7 0.304 
Total Velocity (mm/s) Elbow 85.93±49.05 44.10±15.67 95.55±60.53 71.57±40.85 0.202 
 Wrist 187.55±99.57 99.82±56.90 194.15±133.75 125.43±66.44 0.419 
 Hand 217.25±125.99 112.47±59.28 222.94±146.19 158.62±87.54 0.336 
 Shoulder 105.55±30.72 59.85±20.44 95.88±49.99 84.17±4.39 0.507 
Total Acceleration (m/s^2) Elbow 0.61±0.38 0.30±0.22 0.48±0.27 0.36±0.26 0.529 
 Wrist 1.00±0.66 0.49±0.35 0.75±0.44 0.54±0.30 0.434 
 Hand 1.08±0.85 0.47±0.19 0.81±0.41 0.53±0.29 0.524 
 Shoulder 0.15±0.06 0.09±0.03 0.14±0.06 0.10±0.03 0.612 
Time All segments 26.4±7.4 8.6±1.8 21.8±9.2 7.1±1.4 0.059 
Table 6 Kinematic measures and smoothness quantification parameters pre- and post- BTX treatment 
 
 MAS - Elbow MAS - Wrist MAS - Hand MAS - Shoulder 
NMU -0.055 0.121 -0.792 -0.666 
NJS 0.558 0.249 -0.388 -0.141 
Trajectory 0.750 0.336 -0.422 -0.762 
Time 0.397 -0.209 -0.693 -0.693 
Total_Velocity_Mean 0.376 0.615 0.937* 0.978* 
Total_Acceleration_Mean 0.946* 0.726 -0.234 0.388 
Table 7 Correlations between MAS score and kinematic measures with regard to different upper limb segments 
 
 
The kinematic measures related to the 
movement smoothness are proved better indicators 
for the changes of upper limb functions. The 
AROM gives additional results compared with the 
passive ROM for evaluating the upper limb 
function after BTX treatment. The 3D position 
tracking of 4 different upper limb segments and 
the 3D trajectory tracking help to understand the 
proportional and joint coordination ability for each 
segment. The visualisation of the position tracking 
in 3D provides additional insights. As seen in Fig 
4 (3), the 3-axes of the position tracking for Patient 
4 shows a large number of small spikes in the 
signal which indicates the tremor from the 
patient’s upper limb motion. In Fig. 4 (4) after the 
BTX treatment, it can be seen that the tremor have 
reduced significantly.  
NMU is an important movement smoothness 
quantification parameter, for both BBT and 
drinking test, the value of NMU has reduced on all 
the four upper limb segments which indicate the 
functional recovery of the whole upper limb. It is 
also noted that the changes of NMU is more 
significant on the elbow and wrist segments than 
that of the shoulder and hand segments.  
All the patients were satisfied with system. The 
entire assessment took less 20 mins. The four 
sensor MTx system and the experiment protocol 
can be suitable for daily assessment in clinical 
settings. Besides, the low cost version of the two 
sensor based system (utilising gaming controller) 
can be utilised as the home rehabilitation tool. 
Though this study has only been done on a small 
group of patients, but the collected dataset from 
two different multi-sensor system are adequate for 
evaluation of the proof of concept systems. 
Clinical Indications 
There have been very few studies on the upper 
limb voluntary motor function after BTX 
treatment as most of the study is to focus on 
evaluating the spasticity of the upper limb 
segments after BTX treatment but not includes the 
residual voluntary upper limb functions. 
Moreover, the analysing the upper limb function 
for each of the upper limb segments have gained 
the clinicians a comprehensive way of 
understanding data. 
Conclusion 
This study proves that the inertial sensing systems 
are able to provide kinematic analysis on the 
performance quality of the patients on different 
upper limb segments which current clinical scales 
fails to do so. The reduction in the NJS and NMU 
are the indication of the better motion functionality 
of the upper limb segments. The different changes 
for each upper limb segments show the 
compensation of the movement in order to 
complete in daily tasks. 
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